Home / Press / CMS advises capiton on investment of top-up single-asset...

CMS advises capiton on investment of top-up single-asset fund in portfolio company KD Pharma

30/07/2021

Berlin - Private equity firm capiton has closed a top-up single-asset fund for its fast-growing portfolio company KD Pharma Group (KD Pharma). This top-up fund will provide KD Pharma with the equity financing for additional strategic investments, in particular add-on acquisitions as well as organic growth initiatives to transfer KD Pharma‘s unique technology and service portfolio from its core omega-3 market to adjacent market segments. All parties involved have agreed not to disclose any details of the transaction.

A CMS team provided comprehensive legal advice to capiton regarding the investment in KD Pharma. capiton is a long-standing client and regularly relies on the expertise of CMS. The team also advised capiton on Germany's first GP-led single-asset secondary transaction which also involved KD Pharma Group. 

CMS Germany

Dr. Eva Annett Grigoleit, Partner, Berlin
Dr. Igor Stenzel, Partner, Berlin
Patrick M Lühr, Counsel, Berlin,
Fabian Mayer, Senior Associate, Berlin, all Corporate/M&A
Dr. Jörn Witt, Partner, Hamburg,
Dr. Roland Wiring, Partner, Hamburg
Dr. Susanne Pech, Counsel, Hamburg, all Regulatory
Dr. Rolf Hempel, Partner, Stuttgart, Competition & EU 

Press Contact
presse@cms-hs.com

Related people

Portrait ofEva Annett Grigoleit
Dr. Eva Annett Grigoleit
Partner
Berlin
Portrait ofIgor Stenzel
Dr. Igor Stenzel
Partner
Berlin
Portrait ofPatrick M Lühr
Patrick M Lühr, LL.M. (King's College London)
Counsel
Berlin
Portrait ofJörn Witt
Dr. Jörn Witt, LL.M. (University of London)
Partner
Hamburg
Portrait ofRoland Wiring
Dr. Roland Wiring
Partner
Hamburg
Portrait ofRolf Hempel
Dr. Rolf Hempel
Partner
Stuttgart
Fabian Mayer, LL.M.
Dr. Susanne Pech
Show more Show less